Cargando…

REPLY TO: Interleukin-17: a potential therapeutic target in COVID-19

Detalles Bibliográficos
Autores principales:	Piaserico, Stefano, Meneguzzo, Alberto, Messina, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The British Infection Association. Published by Elsevier Ltd. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7322471/ https://www.ncbi.nlm.nih.gov/pubmed/32610110 http://dx.doi.org/10.1016/j.jinf.2020.06.063

Ejemplares similares

Interleukin-17: A potential therapeutic target in COVID-19
por: Mendoza, Vicky M. Montaño
Publicado: (2020)

Interleukin-17 as a potential therapeutic target for chronic pain
por: Jiang, Xiaojuan, et al.
Publicado: (2022)

Painless Plaques Evolving to Bullae and Painful Erosions on the Penis: A Quiz
por: MENEGUZZO, Alberto, et al.
Publicado: (2023)

Psoriasis and Cardiometabolic Diseases: Shared Genetic and Molecular Pathways
por: Piaserico, Stefano, et al.
Publicado: (2022)

Interleukin-17: Potential Target for Chronic Wounds
por: Hadian, Yasmin, et al.
Publicado: (2019)

Photodynamic Therapy for Primary Cutaneous Extramammary Paget Disease
por: Meneguzzo, Alberto, et al.
Publicado: (2023)

Interleukin-17A (IL-17A): A silent amplifier of COVID-19
por: Maione, Francesco, et al.
Publicado: (2021)

Targeting interleukin-17 receptors
por: Lee, Wen-Hwa, et al.
Publicado: (2015)

Reply to: Do interleukin 17 inhibitors increase risk of respiratory tract infections?
por: Blauvelt, Andrew, et al.
Publicado: (2020)

Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation – Authors' reply
por: Cavalli, Giulio, et al.
Publicado: (2021)

Assessing the importance of interleukin-6 in COVID-19 – Authors' reply
por: Leisman, Daniel E, et al.
Publicado: (2021)

Interleukin-22: a potential therapeutic target in atherosclerosis
por: Luo, Jin-Wen, et al.
Publicado: (2021)

Targeting of interleukin-17 in the treatment of psoriasis
por: Lønnberg, Ann Sophie, et al.
Publicado: (2014)

Interleukin-17 regulation: an attractive therapeutic approach for asthma
por: Park, Seoung Ju, et al.
Publicado: (2010)

Interleukin-17A (IL-17A), a key molecule of innate and adaptive immunity, and its potential involvement in COVID-19-related thrombotic and vascular mechanisms
por: Raucci, Federica, et al.
Publicado: (2020)

Interleukin-17, a salivary biomarker for COVID-19 severity
por: Sharif-Askari, Fatemeh Saheb, et al.
Publicado: (2022)

Time of Onset of Selected Skin Lesions Associated with COVID-19: A Systematic Review
por: Gisondi, Paolo, et al.
Publicado: (2021)

Could Targeted Pharmacotherapies Exert a “Disease Modification Effect” in Patients with Chronic Plaque Psoriasis?
por: Bellinato, Francesco, et al.
Publicado: (2022)

The Interleukine-17 Cytokine Family: Role in Development and Progression of Spondyloarthritis, Current and Potential Therapeutic Inhibitors
por: Davydova, Anna, et al.
Publicado: (2023)

Severe Acute Respiratory Syndrome–Coronavirus-2 Infection and Patients With Lung Cancer: The Potential Role of Interleukin-17 Target Therapy
por: Cafarotti, Stefano
Publicado: (2020)

Mechanistic rationales for targeting interleukin-17A in spondyloarthritis
por: Raychaudhuri, Siba P., et al.
Publicado: (2017)

Revisiting the interleukin 17 family of cytokines in psoriasis: pathogenesis and potential targets for innovative therapies
por: Brembilla, Nicolo Costantino, et al.
Publicado: (2023)

Out of the shadow of interleukin-17A: the role of interleukin-17F and other interleukin-17 family cytokines in spondyloarthritis
por: Yeremenko, Nataliya
Publicado: (2021)

WHO COVID-19 therapeutic guidelines – Authors' reply
por: White, Nicholas J, et al.
Publicado: (2021)

The role of interleukin-22 in lung health and its therapeutic potential for COVID-19
por: Fang, Si, et al.
Publicado: (2022)

Lack of Evidence for an Increased Risk of Severe COVID-19 in Psoriasis Patients on Biologics: A Cohort Study from Northeast Italy
por: Piaserico, Stefano, et al.
Publicado: (2020)

Interleukin 17A: A Potential Target for Its Plausible Roles in the Pathogenesis of Idiopathic Epistaxis
por: Nosratabadi, Reza, et al.
Publicado: (2022)

Interleukin-6 as a Potential Therapeutic Target for Pulmonary Arterial Hypertension
por: Furuya, Yoshiaki, et al.
Publicado: (2010)

IL-17A as a Potential Therapeutic Target for Patients on Peritoneal Dialysis
por: Marchant, Vanessa, et al.
Publicado: (2020)

Targeting the interleukin-17 immune axis for cancer immunotherapy
por: Vitiello, Gerardo A., et al.
Publicado: (2020)

Interleukin-17A and interleukin-23 in morphea
por: Dańczak-Pazdrowska, Aleksandra, et al.
Publicado: (2012)

The role of Interleukin-17A and Interleukin-17E in multiple myeloma patients
por: Lemancewicz, Dorota, et al.
Publicado: (2012)

Arterial Hypertension and Interleukins: Potential Therapeutic Target or Future Diagnostic Marker?
por: Tanase, Daniela Maria, et al.
Publicado: (2019)

Therapeutic potential of targeting IL-17 and IL-23 in sepsis
por: Bosmann, Markus, et al.
Publicado: (2012)

Interleukin-20 is involved in dry eye disease and is a potential therapeutic target
por: Wang, Hsiao-Hsuan, et al.
Publicado: (2022)

HSD17B13: A Potential Therapeutic Target for NAFLD
por: Zhang, Hai-bo, et al.
Publicado: (2022)

Serum interleukin 17A and interleukin 17F in children with inflammatory bowel disease
por: Krawiec, Paulina, et al.
Publicado: (2020)

Association of genetic polymorphism of interleukin-17A & interleukin-17F with susceptibility of psoriasis
por: Kaur, Rajinder, et al.
Publicado: (2018)

Role of Interleukin- (IL-) 17 in the Pathogenesis and Targeted Therapies in Spondyloarthropathies
por: Chyuan, I-Tsu, et al.
Publicado: (2018)

Targeting the Interleukin-23/Interleukin-17 Inflammatory Pathway: Successes and Failures in the Treatment of Axial Spondyloarthritis
por: Wang, Runsheng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sck5moomb7563g358482tra3us